Fidelity Investments
NMRA icon

Fidelity Investments’s Neumora Therapeutics NMRA Stock Holding History

Fidelity Investments’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.95M Buy
3,498,869
+211
+0% +$402 ﹤0.01% 2353
2026
Q1 		$6.82M Buy
3,498,658
+389
+0% +$1.01K ﹤0.01% 2199
2025
Q4 		$6.26M Sell
3,498,269
-3,463
-0.1% -$7.58K ﹤0.01% 2207
2025
Q3 		$6.37M Sell
3,501,732
-934
-0% -$1.51K ﹤0.01% 2158
2025
Q2 		$2.57M Buy
3,502,666
+6,350
+0.2% +$4.81K ﹤0.01% 2403
2025
Q1 		$3.5M Sell
3,496,316
-4,342,261
-55% -$7.44M ﹤0.01% 2273
2024
Q4 		$83.1M Buy
7,838,577
+89,421
+1% +$1.07M 0.01% 1188
2024
Q3 		$102M Sell
7,749,156
-873,312
-10% -$10.2M 0.01% 1089
2024
Q2 		$84.8M Buy
8,622,468
+1,140,103
+15% +$11.8M 0.01% 1109
2024
Q1 		$103M Buy
7,482,365
+1,109,236
+17% +$17.9M 0.01% 1048
2023
Q4 		$109M Buy
6,373,129
+748,776
+13% +$9.19M 0.01% 975
2023
Q3 		$79.4M Buy
+5,624,353
New +$70.3M 0.01% 1070

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Fidelity Investments's NMRA Position: Q2 2026 in Review

Fidelity Investments increased its Neumora Therapeutics (NMRA) stake by 0.01% in Q2 2026, buying an estimated $402 and bringing the position to 3,498,869 shares worth $5.95M. The position accounts for ﹤0.01% of the portfolio, ranked #2353.

Fidelity Investments first reported a position in NMRA in Q3 2023 and has held it in 12 quarters since. The position peaked at $109M in Q4 2023. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Fidelity Investments held 3,498,869 shares of Neumora Therapeutics worth $5.95M as of Q2 2026.
  • Fidelity Investments bought 211 Neumora Therapeutics shares in Q2 2026, an estimated $402.
  • Neumora Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #2353 holding.
  • Fidelity Investments first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Fidelity Investments's Neumora Therapeutics position peaked at $109M in Q4 2023.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.